0001193125-22-285963.txt : 20221116 0001193125-22-285963.hdr.sgml : 20221116 20221115195602 ACCESSION NUMBER: 0001193125-22-285963 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221110 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221116 DATE AS OF CHANGE: 20221115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMARA Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811523849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 221392667 BUSINESS ADDRESS: STREET 1: 1309 BEACON STREET STREET 2: SUITE 300 CITY: BROOKLINE STATE: MA ZIP: 02446 BUSINESS PHONE: 617-206-2020 MAIL ADDRESS: STREET 1: 1309 BEACON STREET STREET 2: SUITE 300 CITY: BROOKLINE STATE: MA ZIP: 02446 8-K/A 1 d408792d8ka.htm 8-K/A 8-K/A
0001672619 0001672619 2022-11-10 2022-11-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2022

 

 

IMARA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39247   81-1523849

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1309 Beacon Street, Suite 300, Office 341

Brookline, MA

     02446
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 206-2020

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   IMRA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Explanatory Note

On November 10, 2022, Imara Inc., a Delaware corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report, among other things, the completion of the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”) pursuant to the Asset Purchase Agreement between the Company and Cardurion Pharmaceuticals, Inc. dated as of September 6, 2022.

As disclosed in the Initial Report, this Current Report on Form 8-K/A is being filed to amend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. No other changes are being made to the Initial Report.

The pro forma financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only and is not necessarily indicative of the pro forma financial position or results of operations that would have been realized had the Asset Sale occurred as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that the Company will experience after the Asset Sale.

This Current Report on Form 8-K/A should be read in conjunction with the Initial Report, which provides a more complete description of the Asset Sale.

 
Item 9.01

Financial Statements and Exhibits.

(b) The unaudited pro forma condensed consolidated financial information of the Company as of and for the nine months ended September 30, 2022, and the unaudited pro forma condensed consolidated financial information of the Company for the fiscal year ended December 31, 2021 as required by Item 9.01(b) are attached as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference.

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Unaudited Pro Forma Condensed Consolidated Financial Information.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    IMARA INC.
Date: November 15, 2022     By:  

/s/ Rahul D. Ballal

    Name:   Rahul D. Ballal, Ph.D.
    Title:   President and Chief Executive Officer
 EX-99.1 2 d408792dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

UNAUDITED PRO FORMA FINANCIAL INFORMATION

On November 10, 2022 (the “Closing Date”), IMARA Inc. (the “Company”) completed the previously announced transaction providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”) to Cardurion Pharmaceuticals, Inc. (“Cardurion”) pursuant to the Asset Purchase Agreement (the “Asset Purchase Agreement”) between the Company and Cardurion dated as of September 6, 2022. In addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet, the aggregate purchase price consisted of an upfront cash payment of $34,750,000 upon closing of the Asset Sale, a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement. The Company will not have any further direct involvement in the development and commercialization of the technology that is subject to the Asset Purchase Agreement. Among other customary closing conditions, the Asset Purchase Agreement was contingent upon obtaining stockholder approval of the arrangement, which occurred on November 10, 2022.

The following unaudited pro forma consolidated financial statements are intended to show how the Asset Sale might have affected the historical financial statements of the Company if the Asset Sale had been completed at an earlier time as indicated therein, and such unaudited pro forma consolidated financial statements are derived from, and should be read in conjunction with, the Company’s historical condensed consolidated financial statements and notes thereto, as presented in the Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2022 filed with the Securities and Exchange Commission (“SEC”) on October 25, 2022 (the “Form 10-Q”) and the Company’s historical financial statements and notes thereto, as presented in the Company’s Annual Report on Form 10-K filed for the fiscal year ended December 31, 2021 filed with the SEC on March 15, 2022 (the “Form 10-K”).

The unaudited pro forma consolidated financial information has been prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed consolidated balance sheet as of September 30, 2022 assumes the transaction had occurred on September 30, 2022. The unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2022 and the year ended December 31, 2021 give effect to the transaction as if it had occurred as of January 1, 2021.

In addition, Regulation S-X permits registrants to reflect adjustments that depict synergies and dis-synergies of the acquisitions and dispositions for which pro forma effect is being given in the Company’s disclosures as management adjustments. The Company has determined not to disclose such adjustments because it does not believe that presentation of such adjustments would enhance an understanding of the pro forma effects of the Asset Sale.

The accounting adjustments to reflect the Asset Sale in the unaudited pro forma consolidated financial statements include:

 

  •  

the sale of the assets related to the PDE9 program (including tovinontrine) pursuant to the Asset Purchase Agreement; and

 

  •  

receipt of the cash proceeds that were payable on the Closing Date in connection with the Asset Sale.

The effects of recording certain adjustments associated with contingent consideration contemplated by the Asset Sale have been excluded because of the uncertainty of payments which were not considered probable of occurring at the time of the Closing Date.

The unaudited pro forma consolidated financial statement information is presented for informational purposes only and is based upon estimates by the Company’s management, which are based upon available information and certain assumptions that the Company’s management believes are reasonable as of the date of this filing. The unaudited pro forma consolidated financial statements are not intended to be indicative of the actual financial position or results of operations that would have been achieved had the Asset Sale been consummated as of the periods indicated, nor does it purport to indicate results which may be attained in the future. Actual amounts could differ materially from these estimates.

The unaudited pro forma consolidated balance sheet as of September 30, 2022 and the unaudited pro forma consolidated statements of operations for nine months ended September 30, 2022 and the year ended December 31, 2021 should be read in conjunction with the notes thereto.

Imara Inc.

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2022

(in thousands, except share and per share data)

 

            Transaction Accounting Adjustments                
     Historical Imara      Operations of
Sold Assets		             Pro Forma
Adjustments		             Pro Forma
Imara		  
     (a)      (b)             (c)            

 

  

Assets

                  

Current assets:

                  

Cash and cash equivalents

    $ 49,491      $ —           $ 32,750        (e )     $ 82,241  

Short-term investments

      6,813        —             —             6,813  

Prepaid expenses and other current assets

      2,800        (566 )       (d )       —             2,234  
  

 

 

     

 

 

        

 

 

        

 

 

  

Total current assets

      59,104        (566 )          32,750           91,288  
  

 

 

     

 

 

        

 

 

        

 

 

  

Total assets

    $ 59,104      $ (566 )        $ 32,750         $ 91,288  
  

 

 

     

 

 

        

 

 

        

 

 

  

Liabilities and stockholder’s equity

                  

Current liabilities:

                  

Accounts payable

    $ 767      $ —           $ —           $ 767  

Accrued expenses and other current liabilities

      1,051        —             —             1,051  
  

 

 

     

 

 

        

 

 

        

 

 

  

Total current liabilities

      1,818        —             —             1,818  
  

 

 

     

 

 

        

 

 

        

 

 

  

Total liabilities

      1,818        —             —             1,818  

Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September 30, 2022; 26,287,264 shares issued and outstanding as of September 30, 2022

      27        —             —             27  

Additional paid-in capital

      235,457        —             —             235,457  

Accumulated other comprehensive loss

      (4 )       —             —             (4 ) 

Accumulated deficit

      (178,194 )       (566 )          32,750           (146,010 ) 
  

 

 

     

 

 

        

 

 

        

 

 

  

Total stockholders’ equity

      57,286        (566 )          32,750           89,470  
  

 

 

     

 

 

        

 

 

        

 

 

  

Total liabilities and stockholders’ equity

    $ 59,104      $ (566 )        $ 32,750         $ 91,288  
  

 

 

     

 

 

        

 

 

        

 

 

  

See accompanying notes to the pro forma consolidated financial statements

Imara Inc.

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Nine Months Ended September 30, 2022

(in thousands, except share and per share data)

 

           Transaction Accounting Adjustments         
     Historical Imara     Operations of
Sold Assets		           Pro Forma
Adjustments		      Pro Forma
Imara		  
     (a)     (b)           (c)     

 

  

Operating expenses:

            

Research and development

    $ 18,760     $ (17,692 )      (d )    $ —        $ 1,068  

General and administrative

      12,253       —           —          12,253  
  

 

 

    

 

 

      

 

 

     

 

 

  

Total operating expenses

      31,013       (17,692 )        —          13,321  
  

 

 

    

 

 

      

 

 

     

 

 

  

Loss from operations

      (31,013 )      17,692         —          (13,321 ) 

Total other income, net:

            

Other expense

      (114 )      —           —          (114 ) 

Interest income

      430       —           —          430  
  

 

 

    

 

 

      

 

 

     

 

 

  

Total other income, net

      316       —           —          316  
  

 

 

    

 

 

      

 

 

     

 

 

  

Net loss

    $ (30,697 )    $ 17,692       $ —        $ (13,005 ) 
  

 

 

    

 

 

      

 

 

     

 

 

  

Net loss per share attributable to common stockholders, basic and diluted

    $ (1.17 )    $ —         $ —        $ (0.49 ) 
  

 

 

    

 

 

      

 

 

     

 

 

  

Weighted-average common shares outstanding, basic and diluted

      26,287,264       —           —          26,287,264  
  

 

 

    

 

 

      

 

 

     

 

 

  

See accompanying notes to the pro forma consolidated financial statements

Imara Inc.

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2021

(in thousands, except share and per share data)

 

           Transaction Accounting Adjustments               
     Historical Imara     Operations of
Sold Assets		           Pro Forma
Adjustments		            Pro Forma
Imara		  
     (a)     (b)           (c)           

 

  

Operating expenses:

              

Research and development

    $ 38,442     $ (36,603 )      (d )    $ —          $ 1,839  

General and administrative

      13,000       —           —            13,000  
  

 

 

    

 

 

      

 

 

       

 

 

  

Total operating expenses

      51,442       (36,603 )        —            14,839  
  

 

 

    

 

 

      

 

 

       

 

 

  

Loss from operations

      (51,442 )      36,603         —            (14,839 ) 

Total other income, net:

              

Other expense

      (175 )      —           —            (175 ) 

Interest income

      233       —           —            233  

Sale of IPR&D asset

      —         —           32,750        (e )      32,750  
  

 

 

    

 

 

      

 

 

       

 

 

  

Total other income, net

      58       —           32,750          32,808  
  

 

 

    

 

 

      

 

 

       

 

 

  

Net (loss) income

    $ (51,384 )    $ 36,603       $ 32,750        $ 17,969  
  

 

 

    

 

 

      

 

 

       

 

 

  

common stockholders, basic and diluted

    $ (2.37 )    $ —         $ 32,750        $ 0.83  
  

 

 

    

 

 

      

 

 

       

 

 

  

Weighted-average common shares outstanding, basic and diluted

      21,661,450       —           —            21,661,450  
  

 

 

    

 

 

      

 

 

       

 

 

  

See accompanying notes to the pro forma consolidated financial statements

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

The unaudited pro forma condensed consolidated financial statements reflect the following notes and adjustments:

 

  (a)

Reflects the condensed consolidated balance sheet as of September 30, 2022 and condensed consolidated statement of operations for the nine months ended September 30, 2022 in the Form 10-Q and the consolidated statement of operations for the year ended December 31, 2021 in the Form 10-K.

 

  (b)

Reflects the consummation of the Asset Sale in accordance with the terms of the Asset Purchase Agreement.

 

  (c)

Reflects the additional transaction accounting adjustments which show how the Asset Sale might have affected the Company’s historical financial statements if the sale had been completed at an earlier time.

 

  (d)

Adjustments represent the elimination of assets to the Asset Sale and the disposed operations. Note that liabilities are not eliminated as liabilities incurred by the Company prior to the Closing Date are excluded form the transaction and not transferred to Cardurion, per the Asset Purchase Agreement.

 

  (e)

To record the net cash proceeds from the Asset Sale paid on the Closing Date of $34.8 million, less estimated closing costs of $2.0 million that are likely to be incurred as part of the consummation of the Asset Sale.

EX-101.SCH 3 imra-20221110.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 imra-20221110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line1 Entity Address, Address Line One Entity Address Address Line2 Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address City Or Town Entity Address, City or Town Entity Address State Or Province Entity Address, State or Province Entity Address Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre-commencement Tender Offer Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Security12b Title Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Amendment Description Amendment Description Entity Central Index Key Entity Central Index Key EX-101.PRE 5 imra-20221110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 10, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Document Period End Date Nov. 10, 2022
Entity Registrant Name IMARA INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39247
Entity Tax Identification Number 81-1523849
Entity Address, Address Line One 1309 Beacon Street
Entity Address, Address Line Two Suite 300
Entity Address, Address Line Three Office 341
Entity Address, City or Town Brookline
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02446
City Area Code 617
Local Phone Number 206-2020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol IMRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Description On November 10, 2022, Imara Inc., a Delaware corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report, among other things, the completion of the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”) pursuant to the Asset Purchase Agreement between the Company and Cardurion Pharmaceuticals, Inc. dated as of September 6, 2022.As disclosed in the Initial Report, this Current Report on Form 8-K/A is being filed to amend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. No other changes are being made to the Initial Report.The pro forma financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only and is not necessarily indicative of the pro forma financial position or results of operations that would have been realized had the Asset Sale occurred as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that the Company will experience after the Asset Sale.This Current Report on Form 8-K/A should be read in conjunction with the Initial Report, which provides a more complete description of the Asset Sale. 
Entity Central Index Key 0001672619
XML 7 d408792d8ka_htm.xml IDEA: XBRL DOCUMENT 0001672619 2022-11-10 2022-11-10 0001672619 8-K/A true 2022-11-10 IMARA INC. DE 001-39247 81-1523849 1309 Beacon Street Suite 300 Office 341 Brookline MA 02446 617 206-2020 false false false false Common Stock, par value $0.001 per share IMRA NASDAQ true false On November 10, 2022, Imara Inc., a Delaware corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report, among other things, the completion of the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”) pursuant to the Asset Purchase Agreement between the Company and Cardurion Pharmaceuticals, Inc. dated as of September 6, 2022.As disclosed in the Initial Report, this Current Report on Form 8-K/A is being filed to amend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. No other changes are being made to the Initial Report.The pro forma financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only and is not necessarily indicative of the pro forma financial position or results of operations that would have been realized had the Asset Sale occurred as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that the Company will experience after the Asset Sale.This Current Report on Form 8-K/A should be read in conjunction with the Initial Report, which provides a more complete description of the Asset Sale.  EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "?;U4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " GV]5]S%[,.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^EB#Z';B^))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BR(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M T+#>0L.21E%"A9@%58BZSNCI8ZHR,GQI:Q;V3&1 M&C7F7\E*.@7Z!]0UOFDJ(2K0[SN5M*SE_7UQ_^%V%G3=V;_^Q M\46P[^#77?1?4$L#!!0 ( "?;U697)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M )]O50I1>F7[!@ KQ@ !@ !X;"]W;W)KG*W AGV@)=KB*HDJ2=G)?OT> M*5ER,X4R]J619-[CX]WQW9$]WPKY3<6,:?*8)IFZZ,5:Y^\' Q7&+*6J+W*6 MX9>5D"G5>)7K@]'S>[L/]WP=:_-A<'F>TS5;,/U;/I=X&]0H$4]9IKC(B&2KB][$?W\5 MC(V!'?$[9UNU]TS,4I9"?#,OL^BBYQE&+&&A-A 4?S9LRI+$(('']PJT5\]I M#/>?=^@?[>*QF"55;"J2KSS2\45OW",16]$BT?=B^PNK%O3.X(4B4?9?LBW' M#H<]$A9*B[0R!H.49^5?^E@Y8L]@[+U@$%0&@>5=3F197E--+\^EV!)I1@/- M/-BE6FN0XYF)RD)+_,IAIR^O15C R9K0+"(WF>;ZB-84UCZ,29@$-D>7Q,Z+J-A]M>RX(Y:+RK:;P[S!MS)KDP&141Y&6K M8]Q(=1YU)=*HIC9R E;)?<_6W*02.-[1M)68&V=V.[F?D-G=M.\@=5J3.CV$ MU"P+AF2 MR38B;@S/\X]/SH+AJ8//6XV@>H<0G$01Q$8=[1[(9XPC7[+6.'9 ^B?>&;EB-,0J\1U:[V*Z)_W^ M_V?ZL!6M3-V0BX(CK^G-RM;#,I=CP+&SWGQOSUE6N M_*90^&Y]?TYM+I2F"?F#YR^J70>B%PR'(Q>WIE+X;HFW,9R@R7V9BAM@Y+ND MSF^J@^]6\,\BA$_FL_PZ\#J9-8(?N-7Y/\QF2A5@UDG0#=M)<*_7=VOS ]=H M,\2*^,&;Y5NR8&&!?'MJY>1&,OEIJZ4(OQV1G$JRH4G!R$]>']T(R;%<%5/I MI-W4@, MV@^21B;]%D_I4K0F7P? [/;>I:I!(_B!6YQW'B,WCV%,LS5[L M8I?<9I=S96^(M"#26H,Y=OZ:"!A*6"/ET%X8%$A?GC"["DB,^:)H*3?:=$," M1RW36+[!;CP>C4_?VKEHDE105"FFU7EY(59B#*&S-R'+(O)!8G<+K&@VNS8(ETUN&HKL_K^$VI3*" M7TS20LM2!+K0*,D)UFMB2"++C%K."Y;KO9B/RI#W)XI$7(6)4!C)RRE^C(;Q M'5==,1U,RD>,7#*SR\M867.NQ+$R*B-E?X31B[YU@FM$L-"-Y264C.G:"'5?SB M2<6Z\M?AOD%400!QM)LQ,[$!Z#XT)D)2Y @&8I8E990Q028TR5B(1IE*CL\\ MBVSKM6&[=&SC#)Q2TC )9BR2,GL%BE_9ML&2:K(511*1F&Y8R0Y];\+_8>93 MM)>7"[M7PM"L=9=4YE>39&K'B$5'("L-9ZY)RJKL7K)GE,L,1K+RW.9H.^E5 MH0L$S<%]?T=L.;8J>\0(;AH<0E?:"L#^ A#?P^.E8NN9I6% ;;1Q /^[R,K[ MY%J''1S,\5*)>C- MT.,]DD^LO>)V7>!X_N@T&/FM5R2#O>MGCI6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG> MW&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4 MD*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF M8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,) M;2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z: M\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9 ML^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E M\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ- MLPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O M-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*= M##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ M P04 " GV]5EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P M#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606 MIW.D5XA-/E M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU M@LD/['X 4$L#!!0 ( "?;U4<.&7J/P$ #P" / >&PO=V]R:V)O M;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=1 M5*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU M!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[ MMP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8? M1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.( M<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W M\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q= MZ*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ )]O5660>9(9 0 SP, !, !; M0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\: MJ_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)X MKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\ MC<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&) M7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\ MP68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B M6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " GV]5 M!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM M;%!+ 0(4 Q0 ( "?;U7W,7LP[0 "L" 1 " :\ M !D;V-0&UL4$L! A0# M% @ )]O50I1>F7[!@ KQ@ !@ ("!# @ 'AL+W=O M7!E&UL4$L%!@ ) D /@( )T6 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 26 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d408792d8ka.htm d408792dex991.htm imra-20221110.xsd imra-20221110_lab.xml imra-20221110_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d408792d8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d408792d8ka.htm" ] }, "labelLink": { "local": [ "imra-20221110_lab.xml" ] }, "presentationLink": { "local": [ "imra-20221110_pre.xml" ] }, "schema": { "local": [ "imra-20221110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 1, "total": 1 }, "keyCustom": 0, "keyStandard": 26, "memberCustom": 0, "memberStandard": 0, "nsprefix": "imra", "nsuri": "http://imaratx.com/20221110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d408792d8ka.htm", "contextRef": "duration_2022-11-10_to_2022-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d408792d8ka.htm", "contextRef": "duration_2022-11-10_to_2022-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imaratx.com//20221110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-22-285963-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-285963-xbrl.zip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�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